<DOC>
	<DOCNO>NCT00911586</DOCNO>
	<brief_summary>The purpose study confirm long ( i.e. , many day ) take reach steady-state testosterone undecanoate administer twice daily .</brief_summary>
	<brief_title>Pharmacokinetic Study Determine Time Steady-state</brief_title>
	<detailed_description>Serum testosterone level obtain hypogonadal ( serum testosterone &lt; 300 ng/dL ) males receive testosterone undecanoate capsule administer twice daily . Serum sample obtain consecutively morning several day one month open-label treatment confirm time steady-state reach .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male , age 1875 Morning serum testosterone ( T ) &lt; 300 ng/dL two occasion Naive androgenreplacement therapy willing washout current T therapy Significant intercurrent disease Abnormal prostate digital rectal exam , elevate PSA , AUA symptom score &gt; 15 history prostate cancer . Serum transaminases &gt; 2 time upper limit normal Serum bilirubin &gt; 2.0 mg/dL Hematocrit &lt; 35 % &gt; 50 % BMI &gt; 36 Untreated , obstructive sleep apnea .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>